Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Here come GMP Grade Cytokines！Free Sample is available！ Here come GMP Grade Cytokines！Free Sample is available！
GMP Human IL-6 Protein (Cat. No. GMP-L06H27) stimulates proliferation of TF-1 human erythroleukemic cell line. The specific activity of GMP Human IL-6 Protein is > 1.00×10^8 IU/mg, which is calibrated against human IL-6 WHO International Standard (NIBSC code: 21/308) (QC tested).
Loaded Biotinylated Human IL-6, epitope tag free, primary amine labeling (Cat. No. IL6-H8218) on SA Biosensor, can bind Human IL-6 R alpha, His Tag (Cat. No. ILR-H4223) with an affinity constant of 45.9 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Lenalidomide | IMID-5013; CDC-5013; CDC-501; CC-5013; IMiD-3; ENMD-0997; STAR-LLD | Approved | Celgene Corp | Revimid (former Brand Name), 瑞复美, Revlimid, Leavdo | United States | Myelodysplastic Syndromes | Bristol Myers Squibb Srlcompany | 2005-12-27 | Lymphoma, T-Cell, Peripheral; Optic Nerve Glioma; Intestinal Neoplasms; Immunoproliferative Small Intestinal Disease; Solid tumours; Bone Marrow Neoplasms; Lymphoma, B-Cell, Marginal Zone; Kidney Neoplasms; Leukemia; Liver Neoplasms; Hematologic Diseases; Leukemia, Erythroblastic, Acute; Leukemia, Promyelocytic, Acute; Leukemia, Myeloid; Ependymoma; HIV Infections; Ovarian Neoplasms; Medulloblastoma; Leukemia, Hairy Cell; Anemia; Paraproteinemias; Pain; Polycythemia Vera; Plaque, Amyloid; Rhabdoid Tumor; Anemia, Refractory, with Excess of Blasts; Glioblastoma; Smoldering Multiple Myeloma; Anemia, Refractory; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Myelodysplastic Syndromes; Hypothalamic Neoplasms; Neoplasms; Leukemia-Lymphoma, Adult T-Cell; Plasmacytoma; Blood Protein Disorders; Graft vs Host Disease; Leukemia, Myelomonocytic, Chronic; Leukemia, Myelomonocytic, Acute; Nerve Degeneration; Lymphomatoid Granulomatosis; Pancreatic Neoplasms; Multiple Myeloma; Leukemia, Megakaryoblastic, Acute; Oligodend | Details |
| Luminol sodium | MP-1032 | Approved | Selvim, Metrio | Immune System Diseases; Psoriasis | null | 1997-01-01 | Coronavirus Disease 2019 (COVID-19); Immune System Diseases; Psoriasis | Details | ||
| Pomalidomide | IMID-4047; CDC-394; CC-4047; IMiD-1 | Approved | Celgene Corp | Pomalyst, Imnovid, Actimid, Pomalyst/Imnovid, 安跃 | United States | Multiple Myeloma | Bristol-Myers Squibb Company | 2013-02-08 | Pulmonary Fibrosis; Atypical Squamous Cells of the Cervix; Sarcoma, Kaposi; Anemia, Sickle Cell; Neurofibromatosis 1; Lymphoma, Non-Hodgkin; Carcinoma, Small Cell; Waldenstrom Macroglobulinemia; Glioma; Primary Myelofibrosis; Sarcoma; Thrombocytosis; Prostatic Neoplasms; Lung Diseases, Interstitial; Medulloblastoma; Central Nervous System Neoplasms; Multiple Myeloma; Hodgkin Disease; Plasmacytoma; Kidney Diseases; Pancreatic Neoplasms; Immunoglobulin Light-chain Amyloidosis; Myeloproliferative Disorders; Graft vs Host Disease; Scleroderma, Systemic; Polycythemia Vera; Bone Marrow Neoplasms; Solid tumours | Details |
| Siltuximab | cCLB-8; CNTO-328 | Approved | Johnson & Johnson | Sylvant | United States | Multicentric Castleman's Disease (MCD) | Janssen Biotech Inc | 2014-04-23 | Psychotic Disorders; Leukemia, Large Granular Lymphocytic; Lymphoma, Non-Hodgkin; Lung Neoplasms; Thrombocytopenia; Colorectal Neoplasms; Castleman Disease; Primary Myelofibrosis; Prostatic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Neoplasms, Plasma Cell; Multicentric Castleman's Disease (MCD); Lung Diseases; Monoclonal Gammopathy of Undetermined Significance; Respiratory Distress Syndrome, Adult; Multiple Myeloma; Bone Marrow Neoplasms; Immunoglobulin Light-chain Amyloidosis; Myelodysplastic Syndromes; Pancreatic Neoplasms; Smoldering Multiple Myeloma; Respiratory Tract Diseases; Schizophrenia; Pneumonia; Carcinoma, Renal Cell; Polycythemia Vera; Kidney Neoplasms; Respiratory Tract Infections; Cytokine Release Syndrome; Head and Neck Neoplasms; Ovarian Neoplasms; Diabetes Mellitus, Type 1 | Details |
| Andrographolide/Sodium Hydrogen Sulfite | Approved | Bacterial Infections | Details | |||||||
| Thalidomide | NSC-66847; NSC-527179; K-17; VP-02; FPF-300; FPF300 | Approved | Celgene Corp | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Mainland China | Leprosy, Lepromatous; Multiple Myeloma | Changzhou Pharmaceutical Factory | 1982-01-01 | HIV Wasting Syndrome; Angiodysplasia; Primary Myelofibrosis; Neuroectodermal Tumors, Primitive; Prostatitis; Colorectal Neoplasms; Osteosarcoma; Lymphoma, Mantle-Cell; Sarcoma, Ewing; Retinoblastoma; Erythema Nodosum; Drug Resistant Epilepsy; Xerostomia; Sarcoma; Pancreatitis, Chronic; Adenocarcinoma, Clear Cell; Lymphoma, Follicular; Arachnoiditis; Carcinoma, Adenosquamous; Gastrointestinal Hemorrhage; Cholangitis, Sclerosing; Prostatic Neoplasms; Pelvic Pain; Neoplasm Metastasis; Stomatitis; Burning Mouth Syndrome; Mycobacterium avium-intracellulare Infection; Amyotrophic Lateral Sclerosis; Melanoma; Myelodysplastic-Myeloproliferative Diseases; Carcinoma, Hepatocellular; Leukemia, Lymphocytic, Chronic, B-Cell; Vascular Malformations; Tuberculosis; Appendiceal Neoplasms; Lymphoma, Non-Hodgkin; Uterine Neoplasms; Anemia, Sideroblastic; Glioma; Leprosy, Lepromatous; Endometrial Neoplasms; Lung Neoplasms; Waldenstrom Macroglobulinemia; Kidney Neoplasms; Thalassemia; Carcinoid Tumor; Lupus Erythematosus, Discoid | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Ensereptide | PXL-01 | Phase 3 Clinical | Promore Pharma | Post-surgical adhesions; Tissue Adhesions; Cicatrix | Details |
| Olokizumab | CDP-6038; Anti-IL6-UCB | Phase 3 Clinical | Ucb | Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Arthritis; Crohn Disease | Details |
| Efprezimod alfa | CD24-Fc; HAS-CD24; CD24-Fc-IgG; MK-7110; MK7110 | Phase 3 Clinical | Oncoimmune Inc | Solid tumours; Hematopoietic stem cell transplantation (HSCT); Leukemia; HIV Infections; Graft vs Host Disease; Myelodysplastic Syndromes; Coronavirus Disease 2019 (COVID-19); Precursor Cell Lymphoblastic Leukemia-Lymphoma; Dyslipidemias; Leukemia, Myeloid, Acute; Melanoma | Details |
| Ziltivekimab | COR-001 | Phase 3 Clinical | Astrazeneca Plc | Myocardial Infarction; Heart Failure; Anemia; Atherosclerosis; Cardiovascular Diseases; Inflammation; Renal Insufficiency, Chronic; Systemic Inflammatory Response Syndrome | Details |
| Clazakizumab | ALD-518; ALD518-003; BMS-645429; BMS-945429 | Phase 3 Clinical | Alder Biopharmaceuticals | Plaque, Atherosclerotic; Arthritis, Rheumatoid; Fatigue; Coronavirus Disease 2019 (COVID-19); Graft vs Host Disease; Rejection of organ transplantation; Arthritis, Psoriatic; Asthma; Cachexia; Crohn Disease; Carcinoma, Non-Small-Cell Lung; Kidney Failure, Chronic; Stomatitis | Details |
| RO-7200220 | RO-7200220 | Phase 3 Clinical | F. Hoffmann-La Roche Ltd | Macular Edema; Diabetic macular oedema | Details |
| PF-04236921 | PF-4236921; PF-04236921; TOUR006; TOUR-006 | Phase 2 Clinical | Pfizer Inc | Arthritis, Rheumatoid; Graves Ophthalmopathy; Lupus Erythematosus, Systemic; Renal Insufficiency, Chronic; Crohn Disease | Details |
| Sirukumab | BA-003; CNTO-136 | Phase 2 Clinical | Glaxosmithkline Plc, Johnson & Johnson Innovative Medicine | Giant Cell Arteritis; Depressive Disorder, Major; Arthritis, Rheumatoid; Lupus Erythematosus, Cutaneous; Coronavirus Disease 2019 (COVID-19); Lupus Nephritis; Polymyalgia Rheumatica; Lupus Erythematosus, Systemic; Asthma | Details |
| KSI-501 | KSI-501 | Phase 2 Clinical | Kodiak Sciences Inc | Retinal Diseases; Wet Macular Degeneration; Diabetic macular oedema; Uveitis | Details |
| Anti-interleukin-6 receptor monoclonal antibody (Biocad) | Phase 2 Clinical | Biocad | Autoimmune Diseases | Details | |
| Isomyosamine | MYMD-1 | Phase 2 Clinical | Mymd Pharmaceuticals Inc | Depression; Anxiety; Hashimoto Disease; Frailty; Coronavirus Disease 2019 (COVID-19); Arthritis, Rheumatoid; Healthy Aging; Inflammation; Sarcopenia | Details |
| FB-704A | FB-704; FB-704A | Phase 2 Clinical | Fountain Biopharma Inc | Arthritis, Rheumatoid; Asthma | Details |
| Gerilimzumab | GB-224; RYI-008; ARGX-109 | Phase 1 Clinical | Argenx Se | Arthritis, Rheumatoid | Details |
| MEDI-5117 | WBP-216; MEDI-5117 | Phase 1 Clinical | Wuxi Apptec Co Ltd, Medimmune | Arthritis, Rheumatoid | Details |
| Tocilizumab biosimilar (Mycenax Biotech) | Phase 1 Clinical | Mycenax Biotech Inc | Arthritis, Rheumatoid | Details | |
| NEX-20A | NEX-20A | Phase 1 Clinical | Nanexa AB | Multiple Myeloma | Details |
| Wogonin | Shandong Buchang Pharmaceuticals Co Ltd, Hefei Cosource Medicine Technology, Daewoong Pharmaceutical Co Ltd, China Pharmaceutical University | Details |
This web search service is supported by Google Inc.
A-Z
